Literature DB >> 3666582

Tumor interaction with vascular endothelium.

H Al-Mondhiry1, V McGarvey.   

Abstract

Clinical and experimental observations suggest that tumor-induced endothelial cell (EC) injury may be one of several initial events in the establishment of tumor metastases. This work investigates tumor-induced EC injury and the interaction between tumor-damaged EC and platelets. We used cultured bovine EC and extracts of four cultured human malignancies. EC injury was assessed by 51Cr and lactic dehydrogenase (LDH) release. Incubation of EC with melanoma, breast carcinoma or lung carcinoma caused significant LDH and 51Cr release, whereas colon cancer seemed ineffective. Increased adhesion of platelets to tumor-injured EC was noted. These observations indicate that certain varieties of tumor cause EC injury. Adhesion of platelets to tumor-injured EC results in the formation of platelet-tumor thrombi at the endothelial surface, an event that may initiate tumor invasion of the vessel wall.

Entities:  

Mesh:

Year:  1987        PMID: 3666582     DOI: 10.1159/000215751

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  4 in total

1.  Addition of both platelets and thrombin in combination accelerates tumor cells to adhere to endothelial cells in vitro.

Authors:  I B Helland; B Klementsen; L Jørgensen
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-03       Impact factor: 2.416

2.  Interaction of human malignant melanoma (ST-ML-12) tumor spheroids with endothelial cell monolayers. Damage to endothelium by oxygen-derived free radicals.

Authors:  F A Offner; H C Wirtz; J Schiefer; I Bigalke; B Klosterhalfen; F Bittinger; C Mittermayer; C J Kirkpatrick
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

Review 3.  Hemostatic changes in patients with brain tumors.

Authors:  L Thoron; E Arbit
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy.

Authors:  E Zuckerman; E Toubi; T D Golan; T Rosenvald-Zuckerman; E Sabo; Z Shmuel; D Yeshurun
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.